Zealand Pharma Stock
StockStockPrice
Frequently asked questions
What is Zealand Pharma's market capitalization?
What is the Earnings Per Share (EPS) for Zealand Pharma?
What are the analyst ratings and target price for Zealand Pharma's stock?
What is Zealand Pharma's revenue over the trailing twelve months?
What is the EBITDA for Zealand Pharma?
What is the free cash flow of Zealand Pharma?
What is the 5-year beta of Zealand Pharma's stock?
How many employees does Zealand Pharma have, and what sector and industry does it belong to?
What is the free float of Zealand Pharma's shares?
Financials
Market Cap
$8.18B5Y beta
0.99EPS (TTM)
-$2.354Free Float
70.44MRevenue (TTM)
$10.84MEBITDA (TTM)
-$154.57MFree Cashflow (TTM)
-$100.35MPricing
Analyst Ratings
The price target is $118.97 and the stock is covered by 9 analysts.
Buy
8
Hold
1
Sell
0
Information
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
298
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker